Discussions with Acerta Pharma BV

RNS Number : 9174I
AstraZeneca PLC
14 December 2015
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.  THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF SECURITIES. 

 

DISCUSSIONS WITH ACERTA PHARMA BV

Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction. 

 

The Company will make a further announcement if and when appropriate.

 

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries

 

 

 


Esra Erkal-Paler

 

UK/Global

+44 20 7604 8030

Neil Burrows

UK/Global

+44 20 7604 8032

Vanessa Rhodes

 

UK/Global

+44 20 7604 8037

Karen Birmingham

UK/Global

+44 20 7604 8120

Jacob Lund

 

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Enquiries



UK



Thomas Kudsk Larsen

 

Oncology

+44 7818 524185

Eugenia Litz

RIA

 

+44 7884 735627

Nick Stone

CVMD

 

+44 7717 618834

Craig Marks

Finance

+44 7881 615764

Christer Gruvris

 

Consensus Forecasts

+44 7827 836825

US



Lindsey Trickett

Oncology, ING

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Dial / Toll-Free


 +1 866 381 7277

 

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal





14 December 2015

 

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGCAPUPAUMC

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings